TNYA — Tenaya Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$0.70
+$0.02 (+2.76%)
Tenaya Therapeutics Inc (TNYA) is a biotechnology company listed on NASDAQ. It is led by Faraz Ali M.B.A., based in 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, with about 70 employees. Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Net income was -$70.4M. TNYA currently screens at market cap $156.0M.
Use this TNYA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TNYA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TNYA SEC filings page. Lician reads the product cache first so this HTML stays unique to Tenaya Therapeutics Inc even when a live quote feed is slow.
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Key Statistics
Market Cap
$155.96M
Volume
925,664
Previous Close
$0.70
Day Range
$0.69 – $0.71
P/B Ratio
1.47
EPS
-$1.31
Revenue
$0.00
Net Income
-$111.13M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
70
TNYA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$111.13M | -$124.08M | -$123.67M | -$72.72M |
| EPS (Diluted) | -$1.31 | -$1.68 | -$2.76 | -$4.10 |
Total Assets
$119.94M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.32M
Operating Cash Flow
-$90.50M
Free Cash Flow
$0.00
Tenaya Therapeutics Inc Company Information
- CEO, Interim Principal Financial Officer & Director
- Faraz Ali M.B.A.
- Headquarters
- 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Website
- www.tenayatherapeutics.com
- Phone
- 650 825 6990
- IPO / Founded
- 2021-07-30
- Sector
- Healthcare
- Industry
- Biotechnology